Drug Database
OX

oxcarbazepine (SPN604 / SPN 804 / oxcarbazepine ER)

✓ Approved

Aequus Pharmaceuticals, Inc. · SCN1A · Small Molecule

What is oxcarbazepine?

oxcarbazepine is a small molecule developed by Aequus Pharmaceuticals, Inc.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesSPN604, SPN 804, oxcarbazepine ER
CompanyAequus Pharmaceuticals, Inc.
Drug ClassSmall Molecule
Molecular TargetSCN1A, SCN2A, SCN3A
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Aequus Pharmaceuticals, Inc.

Mechanism of Action

Molecular Targets

oxcarbazepine acts on 3 molecular targets:

SCN1Asodium voltage-gated channel alpha subunit 1 (DEE6B, FEB3)
SCN2Asodium voltage-gated channel alpha subunit 2 (Na(v)1.2, BFNIS)
SCN3Asodium voltage-gated channel alpha subunit 3 (Nav1.3, NAC3)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

oxcarbazepine is developed for 2 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Nervous system disordersPartial seizures✓ Approved
Psychiatric disordersBipolar disorderPhase III

Related Research Articles

PubMedCureus2026-10-28

Isolated Oral and Esophageal Mucosal Injury as a Rare Oxcarbazepine Adverse Drug Reaction: A Case Report.

De Jesus-Gonzalez Joselyn J, Federico Quinten P QP, Malafronte Patrick P, Champeaux Anne A et al.

Drug-induced mucosal injury may result from direct contact toxicity or immune-mediated adverse drug reactions. Although oxcarbazepine is a recognized etiology of severe hypersensitivity reactions, isolated oroesophageal mucosal injury without cutaneous or systemic involvement has not been previously described. We report a 68-year-old woman who developed severe diffuse esophagitis with concomitant oral mucosal ulceration approximately two weeks after oxcarbazepine initiation, with symptom onset within 24 hours of dose escalation from 150 to 300 mg twice daily. Histologic evaluation demonstrated predominantly lymphocytic esophageal inflammation with no evidence of infectious, eosinophilic, or immunobullous disease. The patient had no rash, peripheral eosinophilia, or systemic organ involvement. A Naranjo score of 7 supported a probable adverse drug reaction. Treatment consisted of discontinuation of oxcarbazepine alone, without the need for immunosuppressive or additional pharmacologic therapy. At five-month follow-up, the patient achieved endoscopic and histologic resolution. This case expands upon the recognized spectrum of oxcarbazepine-associated adverse drug reactions and emphasizes the importance of medication review in patients presenting with diffuse esophagitis and oral mucositis.

PMID 42948823
Read full article →
PubMedActa epileptologica2026-10-28

Pharmacokinetic changes and seizure outcomes in pregnant women taking second-generation antiseizure medications.

Hao Nanya N, Yi Xiaoli X, Zhao Renjie R, Zhang Xuechen X et al.

Effective seizure management in pregnant women with epilepsy poses significant clinical challenges. This study aimed to investigate the pharmacokinetic changes of second-generation antiseizure medications (ASMs) and their association with the deterioration of seizure control in Han Chinese women with epilepsy. Patient clinical data including oral daily doses and seizure frequency were acquired from routine clinical practice. Blood concentrations of ASMs determined by therapeutic drug monitoring (TDM) were used to calculate apparent oral clearance (CL) at preconception and each trimester during pregnancy. The ratio of ASM concentration in each trimester to the preconception baseline concentration (RTC) was compared between patients experiencing seizure deterioration and those maintaining stability. Moreover, receiver operating characteristic (ROC) curve analysis was used to identify the threshold RTC value predicting increased seizure frequency. A total of 52 pregnant patients with epilepsy were initially enrolled in this study. The apparent oral clearance of levetiracetam (LEV) and lamotrigine (LTG) showed a significant increase across all trimesters compared to the nonpregnant baseline. Peak clearance occurred in the third trimester for LTG with a 2.0-fold relative clearance (P < 0.05). Similarly, LEV displayed maximum apparent oral clearance increase during the third trimester, reaching 1.6 folds of baseline value (P < 0.05). As a result, serum concentrations of LEV and LTG significantly decreased during pregnancy compared to non-pregnant baseline levels (P < 0.05). However, the apparent oral clearance and the blood level of oxcarbazepine (OXC) remained stable throughout gestation compared to the preconception baseline. Moreover, the RTC values significantly differed between participants with and without seizure deterioration for all three ASMs, indicating that lower RTCs were associated with seizure worsening. Our study revealed significant pharmacokinetic fluctuations of LEV and LTG in Chinese pregnant women. This highlights the necessity of early therapeutic drug monitoring for newer ASMs and dose adjustments to maintain blood concentrations near the non-pregnant baseline level in pregnant women with epilepsy.

PMID 42947279
Read full article →
PubMedEpileptic disorders : international epilepsy journal with videotape2026-10-28

Comparative efficacy of first-line antiseizure monotherapy in pediatric focal epilepsy: An umbrella review of systematic reviews and meta-analyses.

Karaahmet Aysu Yildiz AY, Bilgiç Fatma Şule FŞ, Yüksel Adnan A

First-line antiseizure medication (ASM) monotherapy remains the recommended initial treatment for pediatric focal epilepsy. Although several ASMs are available, uncertainty persists regarding their comparative efficacy, safety, and tolerability, particularly in children. This umbrella review aimed to synthesize and map the available evidence from systematic reviews and meta-analyses evaluating first-line ASM monotherapies for focal epilepsy, with a focus on informing pediatric treatment decisions. This umbrella review was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidance. Systematic reviews and meta-analyses evaluating first-line ASM monotherapy for focal epilepsy were identified through comprehensive database searches. Data on study characteristics, patient populations, ASM comparisons, epilepsy subtypes, follow-up duration, efficacy, safety, and tolerability outcomes were extracted and synthesized descriptively. Evidence mapping was performed to summarize the findings, and potential overlap of primary studies across the included reviews was considered. Where available, outcome-specific certainty-of-evidence ratings reported by the source reviews using GRADE or CINeMA were also extracted and summarized. Sixteen systematic reviews and meta-analyses were included, comprising randomized controlled trials and individual participant data analyses from pediatric and mixed-age populations. Frequently evaluated ASMs included carbamazepine, lamotrigine, levetiracetam, oxcarbazepine, valproate, phenytoin, and several newer-generation agents. Across the included reviews, no single first-line ASM showed consistent superiority for seizure control outcomes. Selected comparisons suggested tolerability advantages for lamotrigine, levetiracetam, and some newer-generation ASMs; however, these findings were not uniform across outcomes or reviews. Several comparative estimates were imprecise, with confidence intervals encompassing potentially clinically meaningful effects, and substantial heterogeneity was present across epilepsy subtype definitions, patient populations, follow-up durations, and outcome reporting. The frequent inclusion of mixed-age populations further limited the strength and direct applicability of pediatric-specific conclusions. Current umbrella-level evidence does not establish clear superiority of one first-line ASM over another for seizure control in pediatric focal epilepsy. Importantly, the absence of statistically significant differences should not be interpreted as evidence of therapeutic equivalence, because several estimates remain imprecise and clinically meaningful differences cannot be excluded. Interpretation is further limited by the scarcity of pediatric-specific comparative data, the frequent inclusion of mixed-age populations, and methodological and outcome heterogeneity across reviews. Safety and tolerability should therefore be considered alongside efficacy when individualizing treatment selection. Well-designed pediatric-specific comparative studies using standardized outcome measures are needed to strengthen evidence-based treatment recommendations.

PMID 42949619
Read full article →
PubMedPharmaceutics2026-10-27

Physiologically Constrained Deep Learning in Physiologically Based Pharmacokinetic Modeling: Virtual Patient Generation, Machine-Learned Scaling Laws, and Pediatric Precision Dosing.

Zhang Lei L, Xu Yichao Y

Physiologically based pharmacokinetic (PBPK) modeling is now central to pediatric dose selection, because clinical sampling in children is ethically constrained and simple weight-based scaling is unreliable while organ function and enzyme activity are still maturing. Three bottlenecks limit classical PBPK in this setting, namely building physiologically coherent virtual patient populations, extrapolating drug disposition across species and age, and estimating many mechanism-linked parameters from sparse data. Over the past five years, deep learning has begun to address each. Generative models constrained by physiological knowledge create virtual patients that preserve realistic correlations and whole-body coherence. Graph networks and neural ordinary differential equations learn continuous scaling and maturation relationships instead of relying on fixed exponents. Physics-informed networks and surrogate emulators estimate mechanistic parameters and quantify uncertainty in data-poor pediatric settings. This review surveys these developments, organizes them by the PBPK workflow they serve, and links them to precision dosing of three antiepileptic drugs, lacosamide, lamotrigine, and oxcarbazepine. Unlike earlier surveys focused on concentration prediction and therapeutic drug monitoring, we keep the mechanistic model in the foreground, treating the virtual patient as the unit of simulation. We also discuss open problems, including validation standards for generated populations, the regulatory qualification of learning-enhanced PBPK, uncertainty reporting, and the prospect of foundation models of pharmacokinetics. Throughout, we distinguish methodological maturity from demonstrated clinical benefit.

PMID 42942788
Read full article →
PubMedBMC pregnancy and childbirth2026-10-27

Prenatal antiseizure medication exposure and offspring structural and neurodevelopmental outcomes: an umbrella review of systematic reviews and meta-analyses.

Li Yulong Y, Fu Yutong Y, Duan Yifei Y, Shi Fanfan F et al.

Review-level evidence on prenatal antiseizure medication (ASM) exposure is difficult to interpret because outcome domains are often synthesized separately, primary studies overlap, and comparator frameworks and certainty vary. We aimed to calibrate evidence across structural and neurodevelopmental outcomes. We conducted an anchor-based umbrella review of systematic reviews and meta-analyses (PROSPERO: CRD420251142541), searching four databases through December 31, 2025. One prespecified anchor review represented each drug-outcome-comparator question; overlapping reviews were not combined into second-order pooled estimates. AMSTAR 2, corrected covered area, GRADE, and directional umbrella-credibility classes were applied, with NS assigned when the 95% confidence interval included the null. Fourteen reviews were included: nine structural and five neurodevelopmental. All had Low or Critically Low AMSTAR 2 confidence, and ASD/ADHD review overlap was very high (CCA, 28.1%). Valproate showed the most consistent retained pattern, including Class I credibility for combined major congenital anomalies and the most credible retained neurodevelopmental signal for autism spectrum disorder (adjusted hazard ratio, 3.10; 95% CI, 2.24-4.28; Low certainty; Class II). Topiramate showed an oral-cleft signal with Low certainty and Class III credibility. The lamotrigine estimate for major congenital anomalies was NS, whereas the orofacial-cleft estimate excluded the null but had Very Low certainty (OR, 1.42; 95% CI, 1.05-1.92; Class IV). Other retained neurodevelopmental anchors had Very Low certainty and were Class IV or NS; no independent pairwise neurodevelopmental anchor was available for carbamazepine, oxcarbazepine, topiramate, or levetiracetam. Review-level evidence was most consistent for valproate and aligned with its established structural and neurodevelopmental risks. NS or Very Low-certainty findings for non-valproate ASMs should not be interpreted as evidence of no risk. Comparative safety requires individualized risk-benefit assessment rather than binary safety classifications.

PMID 42934576
Read full article →
PubMedTherapeutic drug monitoring2026-10-23

Clinical Interactions Between Antiseizure Medications and Direct Oral Anticoagulants: A Scoping Review on Therapeutic Failures and Knowledge Gaps.

Cancellerini Chiara C, Esposto Roberta R, Caravelli Alice A, Vignatelli Luca L et al.

Antiseizure medications (ASMs) are often coprescribed with direct oral anticoagulants (DOACs). The pharmacokinetic (PK) interactions between ASMs and DOACs may result in altered exposure to anticoagulants, potentially increasing the risk of thromboembolic events or bleeding. This review summarizes the clinical evidence on drug-drug interactions between ASMs and DOACs. In accordance with PRISMA-ScR guidelines, a systematic literature search was conducted in PubMed (up to November 2025). All clinical reports and observational datasets reporting the concomitant use of at least 1 ASM and DOAC were included. ASM-DOAC combinations, PK findings, and reported clinical outcomes are presented. Thirty studies were included. Most reports involved enzyme-inducing ASMs (carbamazepine, phenobarbital, primidone, and oxcarbazepine), which were consistently associated with subtherapeutic DOAC plasma concentrations and severe clinical failures. Doubling the DOAC dose did not prevent these events in several cases. Rivaroxaban and apixaban were the most frequently described DOACs, whereas clinical data for edoxaban were limited. Evidence of non-enzyme-inducing ASMs, such as levetiracetam and valproic acid, was limited. Although enzyme-inducing ASMs compromised DOAC efficacy, the available clinical evidence was fragmented and prone to publication bias. The observed variability in interactions involving noninducing ASMs such as levetiracetam underlines the clinical complexity that may exceed theoretical PK predictions. Given the unpredictability of these interactions and the failure of empirical dose adjustments, a standardized approach for therapeutic drug monitoring and prospective, comparative trials are essential to guide personalized therapy in this high-risk population.

PMID 42909474
Read full article →

+2627 more articles available with a free account

Sign up free to view all articles →

Ask about oxcarbazepine